Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19
N/A
The goal of this study is to assess serious adverse events associated with ...
Status
Completed
Location
CMIC Co., Ltd
Start Date
2022-11-15
Trial ID
NCT05894590
Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
PHASE1
GC004 is a Phase I trial to evaluate the safety and the immune responses of...
Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine
PHASE2
The main purpose of this Phase II study was to assess the safety and immuno...